Biologics against IL-6 and IL-6 receptors: dose and interval tested in phase II and III clinical trials
| Target molecules | Biologics | Antibody | Route of administration | Dose | Intervals |
| IL-6R (D2) | Tocilizumab | Humanised | IV (8 mg/kg) SC | 480 mg (60 kg) 162 mg | 4w 1–2 w |
| IL-6R (D2) | Sarilumab | Human | SC | 150 mg 200 mg | 2w |
| IL-6 (site 1) | Sirukumab | Human | SC | 50 mg 100 mg | 2–4 w |
| IL-6 (site 1) | Clazakizumab | Humanised | SC | 25 mg 100 mg 200 mg | 4w |
| IL-6 (site 3) | Olokizumab | Humanised | SC | 60 mg 120 mg 240 mg | 2–4 w |
| IL-6/sIL-6R complex | Olamkicept | Human | IV | 300 mg 600 mg | 2w |
IV, intravenous; SC, sucutaneous; w, weeks.